Symposium “Innovating Cancer Care Through De-escalation Studies”. Save the date.

De-escalation trials are important because they aim to reduce the intensity of medical treatments, improving patients’ quality of life and well-being by minimising toxicity and side effects—without compromising the effectiveness of cancer treatment.

With this symposium, we aim to identify and address the challenges and requirements necessary for the successful initiation of de-escalation trials. Our long-term goal is to improve their quality and increase the number of such trials. The symposium is organized in collaboration with the European Academy of Cancer Sciences and the ARC French Foundation for Cancer Research.

Key details:

• Date: 05-06 March 2026
• Location: NKI, Amsterdam , The Netherlands
• Format: Physical
• Reach: Open for everyone, up to 200 participants
• Target audience: Researchers, clinicians, statisticians, European Medicine Agency, patient representatives, pharmaceutical industry, health insurance companies, leadership of EUnetCCC institutions
• Registration link/details: Registration link will come soon

Agenda highlights:

• Session 1: De-escalation: Biomarkers and Patient perspective.
• Session 2: Modality-focused innovations (Radiotherapy, Immunotherapy, Surgery).
• Session 3: Panel discussion-1 “How to identify who would gain from de-escalation?”
• Session 4: Case studies in de-escalation.
• Session 5: Regulations, Resources and Return on Investment in De-escalation trials.
• Session 6: Panel discussion-2 How to realize de-escalation trials?

Contact details:

For inquiries, please contact: ievail@ous-hf.no